Ranbaxy Laboratories on Thursday said that it had received final approval from US Food and Drug Administration to manufacture and market Ciprofloxacin.
The company has received the nod for manufacturing Ciprofloxacin tablets 250 mg, 500 mg and 750 mg.
"We will begin shipping the widely prescribed anti-infective immediately and will be able to provide product to our customers as of today," Ranbaxy Pharmaceuticals Inc.s sales and marketing vice president James Meehan said in a statement in New Delhi.
Sales of anti-infective Ciprofloxacin tablet are estimated to be at $1.4 billion, while its immediate sale prospects are pegged at $1 billion, it said.